IL10 and B-cell chronic lymphocytic leukemia: Ibrutinib (52) and ruxolitinib (Figure 1E) both decrease IL-10 in CLL patients but, unlike ruxolitinib, ibrutinib deactivates CLL cells in vivo (16).